<DOC>
	<DOCNO>NCT01920854</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics fix ascend dos intravenously administer Soluble Ferric Pyrophosphate</brief_summary>
	<brief_title>A Single Ascending Dose Study Soluble Ferric Pyrophosphate Administered Intravenously Healthy Volunteers .</brief_title>
	<detailed_description>- A total 48 healthy volunteer study . - Depending safety profile completion high dose cohort , additional 2 cohort subject may study . - Doses SFP may modify , depend PK safety finding dose level . - Cohorts may drop safety tolerability discussion sponsor . - There 6 active 2 placebo subject study cohort . - Subjects Cohorts 1-3 receive ascending dose SFP intravenous infusion 4 hour . - Subjects Cohorts 4-6 receive ascending dose SFP intravenous infusion 12 hour . All subject confine CRC 1 day prior study drug administration 2 additional day safety assessment completion test procedure .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>1 . Age 1855 inclusive time consent . This inclusion criterion assess first screen visit . 2 . Male nonpregnant , nonlactating female least 90 day postpartum . 3 . Subject willing comply applicable contraceptive requirement protocol . 4 . Satisfactory medical assessment clinically significant relevant abnormality medical history , physical examination ( PE ) , vital sign , electrocardiogram ( ECG ) laboratory evaluation ( hematology , biochemistry , urinalysis ) assess Investigator . 5 . An understanding , ability willingness fully comply study procedure restriction . 6 . Ability provide write , personally sign date informed consent participate study , accordance International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) Guideline E6 applicable regulation , complete studyrelated procedure . 7 . Body Mass Index ( BMI ) 20.0 32.0 kg/m² inclusive . This inclusion criterion assess first screen visit . 8 . Subjects must agree discontinue iron preparation 14 day prior study drug administration . 1 . Current recurrent disease ( e.g . cardiovascular , renal , liver , gastrointestinal , malignancy condition ) could affect action , absorption disposition investigational product utilized study , could affect clinical laboratory assessment . 2 . Hemoglobin &lt; 11 g/dL Hematocrit &lt; 30 % . 3 . Serum iron concentration ≤ 70 µg/dL ( male female ) . 4 . Current relevant previous history physical psychiatric illness , medical disorder may require treatment make subject unlikely fully complete study , condition present undue risk investigational product study procedure . 5 . Significant illness , judge investigator , within 2 week first dose investigational product . 6 . Current use medication ( include prescription , counter [ OTC ] , herbal homeopathic preparation ) within 14 day first dose investigational product . Exceptions hormonal replacement therapy , hormonal contraceptive , acetaminophen nonsteroidal antiinflammatory drug . 7 . Known suspected intolerance hypersensitivity iron contain product ( ) . 8 . History alcohol substance abuse within last year . 9 . A positive screen cotinine , alcohol drug abuse . 10 . Male subject consume 21 unit alcohol per week three unit per day . Female subject consume 14 unit alcohol per week two unit per day . 1 alcohol unit =1 beer = 1 wine ( 5oz ) = 1 liquor ( 1.5 oz. ) . 11 . A history positive human immunodeficiency virus ( HIV ) antibody screen , Hepatitis B surface antigen ( HBsAg ) Hepatitis C virus ( HCV ) antibody screen . 12 . Use tobacco form ( e.g. , smoke chew ) nicotinecontaining product form ( e.g . gum , patch ) . Exusers must report stop use tobacco least 30 day prior receive first dose investigational product . 13 . Routine consumption five unit caffeine per day subject experience caffeine withdrawal headache . One caffeine unit contain follow item : one 6oz . cup coffee , two 12oz . can cola , one 12oz . cup tea , three 1oz . chocolate bar . 14 . Donation blood blood product ( e.g. , plasma platelet ) within 60 day prior receive first dose investigational product . 15 . Use another investigational product within 30 day prior receive first dose investigational product active enrolment another drug vaccine clinical study . 16 . Pregnancy intention become pregnant complete study drug treatment . 17 . Current medical status , investigator opinion , would preclude participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Soluble Ferric Pyrophosphate , Pharmacokinetics , Iron , Hemodialysis</keyword>
</DOC>